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Abstract
Heparanase promotes tumor invasion and metastasis in several malignancies including breast cancer. However, the roles
and regulation mechanisms of heparanase during breast cancer progression are still not fully understood. The aim of this
study is to determine the differential regulation of heparanase gene expression in specific stages of breast cancer by DNA
methylation. We detected levels of heparanase expression and DNA methylation patterns of its promoter in breast cancer
cell lines (MCF-7 and MDA-MB-435) and clinical tissues, respectively. It has been observed that heparanase is highly
expressed in the invasive MDA-MB-435 cells with low methylation modification in the heparanase promoter. In contrast,
lower expression of heparanase in MCF-7 cells is accompanied by higher methylation in the promoter. Treatment of MCF-7
cells with 5-aza-29-deoxycytidine (5-aza-dC), a potent demethylating agent, results in induction of heparanase expression
and higher invasion potential in vitro and leads to an advantage of tumor formation in vivo. In 54 tissue samples, cancer
samples at late stages (stage IV) showed the highest heparanase expression accomplished by little DNA methylation. On the
contrary, methylation prevalence is highest in normal tissue and inversely correlated with heparanase expression. A
significant correlation between DNA methylation and clinical stage was demonstrated (p= 0.012). Collectively, these results
demonstrate that DNA methylation play the regulation role in heparanase gene in different stages of breast cancer and
present a direct effect on tumor progression.
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Introduction
The mammalian heparanase is the only endo-b-D-glucuroni-
dase responsible for the degradation of heparan sulfate (HS) chains
from heparan sulfate proteoglycans (HSPGs), which is the main
polysaccharide component of the extracellular matrix (ECM) and
basement membrane (BM) [1–2]. Taking into account the fact that
degradation of ECM and BM comprises an initial and essential
step for cancer cells to invade and metastasize, it is plausible that
overexpression of heparanase may facilitate many aspects of tumor
development, including migration, invasion and metastasis.
Indeed, a large number of studies have clearly linked heparanase
expression with the process of tumorigenesis and invasion in a
wide number of malignancies, including breast cancer [3–4].
Breast cancer is the most common malignant disease affecting
women of all age group globally. Despite of recent improvements,
the mortality rate of breast cancer is still as high as around 20% at
5 years, in which most patients died from subsequent metastasis
often occurring in several preferential sites including bone, lung,
liver and brain [5]. Heparanase is closely associated with breast
tumorigenesis, invasion and metastasis. A number of studies
showed that overexpression of heparanase mRNA and protein was
observed both in the in situ and invasive components of ductal and
lobular origins [6]. In breast carcinoma cell lines, its abundance
and enzymatic activity correlate with the aggressiveness. Similarly,
the heparanase are preferentially overexpressed in human breast
tumors when compared with the normal counterpart [7]. The
correlation between heparanase expression and estrogen receptor
(ERs) levels confirmed by tissue array further signified its clinical
relevance [8]. For in vitro systems, cell models demonstrated that
silencing heparanase in breast cancer cells could decrease their
invasion and adhesion [9]. It is also the case in xenograft animals
that overexpression of heparanase in low-metastatic tumor cells
confers a highly invasive phenotype [10]. Although a significant
correlation of heparanase overexpression is coupled with the
progression of breast cancer, the underlying mechanisms remain
unclear.
Aberrant patterns of DNA methylation in cancers are
commonly observed, with a global hypomethylation of whole
genome accompanied by region-specific hypermethylation [11–
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12]. Because cancer progression requires many changes in the
normal program of gene expression, it stands to reason that
aberrations in DNA methylation play a critical role in the changes
in gene expression involved in cancer progression and metastasis
[13]. Recently, methylation of heparanase promoter has also been
involved in its expression regulation in cancer cell lines [14].
However, previous works also indicated that not all tumor cells
expressed heparanase, which indicate that there are different
regulatory mechanisms of heparanase expression among tumors.
Besides, although heparanase expression and its function in tumor
invasion have been well studied, little is known about the
epigenetic mechanism that governing the expression of heparanase
transcription in breast cancer with different potentials of invasion
and metastasis.
To investigate whether DNA methylation is associated with the
regulation of heparanase expression during breast cancer progres-
sion, we performed detailed methylation analysis by methylation-
specific PCR (MSP) combined with pyrosequencing in breast cell
lines and clinical samples with different invasion capacity. First,
the methylation patterns of the 59-regulatory region of heparanase
gene were evaluated in MCF-7 and MDA-MB-435 cells, two cell
lines representing the early and the late stages of the disease,
respectively. Further, we determined the effect of 5-aza-29-
deoxycytidine (5-aza-dC), an inhibitor of DNA methyltransferase,
on heparanase expression and invasion capacity of both cell lines
in vitro. The effect of drug treatment on tumorigenesis of MCF-7
was further assessed by a xenograft model in vivo. Finally, clinical
specimens with different invasive stage were tested to identify
whether there is a correlation between DNA hypomethylation and
heparanase overexpression during breast cancer progression.
Materials and Methods
Ethics Statement
Access to patient samples and anonymous analysis of data was
approved by the Institutional Review Board for Human Research
at Binzhou Medical College (BZMC-JLF-201012). Written
informed consents were obtained from all participants, and all
procedures were approved by the ethics board of Binzhou Medical
College. All animal experiments were approved by the Binzhou
Medical College Animal Care Committee. Animal care protocols
conducted were in accordance with animal care committee
guidelines to minimize pain and discomfort to animals.
Cell Lines and experiment design
MCF-7 and MDA-MB-435 cells were obtained from the
Shanghai Institute of Biochemistry and Cell Biology, Shanghai,
China. Cells were maintained in Dulbecco’s Modified Eagle’s
medium (DMEM) containing glucose at 4.5 g/L supplemented
with 10% fetal calf serum (FCS), L-glutamine and 1% penicillin-
streptomycin (Invitrogen Gibco, USA). The cells were incubated
under a humidified atmosphere of 5% CO2 at 37uC. In the 5-aza-
dC treatment group, MCF-7 and MDA-MB-435 cells were treated
for 7 days with 5-aza-dC (Sigma Aldrich, Ontario, Canada) at
final concentrations of 0.5 mM, 5 mM and 10 mM in the regular
medium. The medium in the wells was replaced with fresh
medium twice a week for both control and treatment groups by
maintaining the desired concentration of the drug and subcultured
when the cells were about 80–90% confluent.
Tissue samples
All tissue samples were collected from surgical specimens of
patients who underwent a mastectomy at the Affiliated Hospital of
Binzhou Medical Colledge, Binzhou, China. A total of 44 patients
with infiltrating ductal carcinoma were enrolled. The tumor-node-
metastasis (TNM) stages were determined using the official
classification method (Stage I: n = 26; Stage IV: n= 18) [15].
These patients did not receive chemotherapy or radiotherapy
before surgical operation. Ten normal breast tissues obtained from
surgically removed tissues from patience with fibroadenoma as
control.
Methylation-specific PCR (MSP)
Genomic DNA from cells and tissues was extracted with the
DNeasy Tissue Kit (Qiagen Inc., Valencia, CA) according to the
manufacturer’s instructions. After genomic DNA quantification,
1 mg of genomic DNA underwent bisulfite modification utilizing
the EZ DNA Methylation-Direct Kit (Zymo Research, Orange,
CA, USA). The bisulfite-converted DNA was resuspended in Tris-
EDTA (TE) buffer and stored at 280uC until the samples were
ready for analysis.
Modified DNA was amplified in a total volume of 20 ml solution
containing 16PCR buffer, 1.5 mM MgCl2, 0.2 mM of each
primer, 200 mM of each dNTP and 1 U Platinum Taq Polymerase
(Life Technologies, Carlsbad, CA). Primers were designed to
detect the methylation status of CpG sites using the MethPrimer
program (http://itsa.ucsf.edu/,urolab/methprimer) [16]. Primer
sequences for unmethylated PCR (MSP-U) and methylated
reaction (MSP-M) were listed as in Table 1. Final products were
electrophoresed for 20 min at 100 V in a 2% agarose gel. A single
band in unmethylated PCR product indicated both alleles of
heparanase gene were unmethylated. The presence of a product
only in the methylated reaction indicated both alleles of
heparanase gene were methylated. Samples that were positive
for both methylated and unmethylated reactions were classified as
having partially methylated heparanase alleles. Both complete
methylation and partial methylation are defined as positive for a
given sample.
Characterization of heparanase methylation by
pyrosequencing
To quantify the pattern of DNA methylation in heparanase
promoter, pyrosequencing was performed using bisulfite converted
DNA from cell lines or tissues above mentioned. Bisulfate treated
DNA was then eluted in 20 ml volume and 1 ml of it was used for
PCR amplification. PCR was performed with one of the PCR
primers biotinylated to allow purification of single-stranded DNA
templates. The reaction contained the following components:
3.0 mM MgCl2, 200 mM dNTPs, 0.2 mM primers, 1 U Platinum
Taq Polymerase (Life Technologies, Carlsbad, CA) and 10 ng of
bisulfite-converted DNA per 50 ml reaction. PCR cycling condi-
tions were: 94uC615 min; 45 cycles of 94uC630 s, 50uC630 s
and 72uC630 s; and final extension of 72uC65 min. Following
purification, 20 ml PCR products were sequenced by the
Pyrosequencing PSQ96 HS System (PSQ H96A, Qiagen Pyrose-
quencing, Valencia, CA, USA). The sequencing primers were
designed by using PyroMark Assay design software ver. 2.0.1.15
(Qiagen, Valencia, CA, USA). The assay was designed to evaluate
the methylation status of 7 CpG sites in one sequencing reaction.
The primer sequences are described in Table 1. The methylation
status of each locus was analyzed individually as a T/C SNP using
Pyro Q-CpG Software (Qiagen Pyrosequencing), which converts
pyrograms to numerical values for peak heights and calculates the
proportion of methylation at each base as a C/T ratio. Then, the
average methylation rate of heparanase in a given sample across
these 7 CpG sites was obtained.
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RNA extraction, semi-quantitative RT-PCR and Real-time
RT-PCR
Total cellular RNAs from MCF-7 and MDA-MB-435 with/
without drug treatment groups and tissue RNA were extracted
using TRIzol (Invitrogen) according to the manufacturer’s
protocol. The primers used for semi-quantitative reverse tran-
scription–polymerase chain reaction (RT-PCR) and Real-time
RT-PCR were designed based on the heparanase mRNA
sequence (GenBank accession number: AF144325) and listed in
Table 1. Human glyceraldehyde-3-phosphate dehydrogenase
(GAPDH, GenBank accession number: BC083511) was served
as internal control. For semi-quantitative RT-PCR, the cDNA was
amplified in a PCR machine (Eppendorf) under the following
conditions: 95uC65 min; 30 cycles of 95uC630 s, 55uC630 s and
72uC630 s; and final extension of 72uC65 min. The PCR
products were separated by 1.5% agarose gel electrophoresis
and stained with ethidium bromide. Real-time RT-PCR with
QuantiTect SYBRGreen Kit (Qiagen) was performed using
Rotor-Gene RG3000 PCR cycler (Corbett Research): An initial
denaturation at 95uC for 5 min, followed by 35 cycles of 95uC for
30 s, 55uC annealing for 20 s, and extension at 72uC for 20 s.
Fluorescence was detected at 585 nm at each extension step of
72uC. Relative expression levels were normalized to the expression
of GAPDH mRNA and calculated by the 22DDCt method.
Western blots
MCF-7 and MDA-MB-435 with/without drug treatment were
lysed in lysis buffer (10 mM HEPES, 142.5 mM KCl, 5 mM
MgCl2, 1 mM EDTA, 0.2% Nonidet P-40, 0.1% aprotinin, and
1 mM phenylmethylsulfonyl fluoride (PMSF), pH 7.2) at 4uC for
30 min, and the lysates were centrifuged (12,000 g) at 4uC for
15 min. Total protein (25 mg) was subjected to 10% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
and then electro-transferred to PVDF membranes (Millipore,
Boston, USA). After being blocked with 5% fat-free milk in Tris-
buffered saline Tween-20 (pH 7.6), the PVDF membranes were
incubated with primary antibodies against heparanase (1:500,
Santa Cruz Biotechnology, Santa Cruz, USA) and GAPDH
(1:1000, Santa Cruz Biotechnology, Santa Cruz, CA) overnight at
4uC, followed by HRP-conjugated secondary antibody. Immuno-
reactive bands were detected using the Chemilucent ECL
detection system (Millipore). Optical band density was quantified
by the Image J software (version 1.43, NIH, Bethesda, USA).
Analysis of Cell cycle distribution
Cell cycle distribution was monitored by flow cytometry
analysis. Briefly, Untreated MCF-7 and MDA-MB-435 cells were
used as negative controls. Cells were treated with 5-aza-dC alone
or in combination with 1 mM OGT2115, a heparanase inhibitor
(Tocris Bioscience, Bristol, UK), respectively [17]. Cells with or
without treatment were trypsinized, washed with phosphate-
buffered saline (PBS) and fixed with 75% ethanol overnight at
220uC. The cells were washed twice with 16PBS and added 1 ml
of propidium iodide (PI, Sigma, USA) staining solution (50 mg/ml)
to cell pellet. Then, 50 ml of RNase A stock solution was added
and incubated for 3 h at 4uC. The cell cycle was analyzed by a
flow cytometry (Beckman Coulter, Inc., USA).
Boyden chamber Matrigel invasion assay
Cell invasion assays were performed as previously described
[18]. Briefly, Untreated MCF-7 and MDA-MB-435 cells were
used as negative controls. Cells were treated with 5-aza-dC alone
or in combination with 1 mM OGT2115, respectively. BD
Matrigel Basement Membrane Matrix (BD BioScience, concen-
tration approx. 9 mg/ml) was mixed 1:1 with PBS was allowed to
polymerize in transwell inserts (Corning) for at least 1 hour at
37uC. Total 56105 cells with/without treatment in 0.1 ml of
serum-free medium were plated in the upper chamber containing
the Matrigel-coated membranes. Serum-containing media acted as
chemo-attractants in the lower chambers. After incubation for
48 h, the invaded cells at the bottom of the membrane were
stained with 0.1% crystal violet and counted under a light
microscope with a 6400 magnification. Ten randomly selected
fields were examined and the average number of cells invaded was
calculated.
In vivo tumorigenicity assay
Twelve female BALB/c nude mice, 5–6 weeks old, were
obtained from the Institute of Zoology, Chinese Academy of
Sciences (Beijing, China)., and were randomly divided into four
groups: control (untreated, n= 3), 0.5 mM (n= 3), 5 mM (n= 3)
and 10 mM (n= 3). Before injection, MCF-7 cells were maintained
in the regular medium containing 5-aza-dC with the desired
concentration for 72 h. On day 4, 100 ml of single cell suspensions
(2.06107 cells/ml) from untreated and treated groups were
subcutaneously inoculated into lower back of nude mice. One
week before inoculation, a 60-d release estrogen pellet (0.72 mg b-
estradiol, Innovative Research of America) was implanted
Table 1. Primer sets used for RT-PCR, Real-time RT-PCR, MSP and pyrosequencing.
Primer set Primers Sequence
Product size
(bp) Application
HPA Forward Reverse 59- ATCTTTGGCCTAAATGCGTTAT -39 59- CATCTTAGCCGTCTTTCTTCG -39 282 RT-PCR
Forward Reverse 59-GAATGGCCCTACCAGGAGCA-39 59-TCCAGTCCTGAGCAGTTTGC-39 122 Realtime RT-PCR
GAPDH Forward Reverse 59- AAGGTCGGAGTCAACGGATTT -39 59- AGATGATGACCCTTTTGGCTC -39 351 RT-PCR
Forward Reverse 59-ACCACAGTCCATGCCATCAC-39 59-AGTAGAGGCAGGGATGATGT-39 108 Realtime RT-PCR
HPA/MSP Forward Reverse 59- TATTCGAGGGTTAGAGGGATATTC -39 59- GAAAATAACCGAAATCCAAACG -39 193 MSP-M





59- TTTATTAGAGGGTTAGAGGGATATT -39 59- Biotin-
AACATCCCCAACCAAACTTCCT -39 59-GGGATATTAGGAGTTATTAGAATGG-39
119 pyrosequencing
Abbreviations: HPA: heparanase; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; MSP: methylation-specific PCR; MSP-U: amplicons for unmethylated MSP; MSP-
M: amplicons for methylated MSP; Pyro: pyrosequencing.
doi:10.1371/journal.pone.0092190.t001
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subcutaneously in each mouse. Tumor growth was evaluated by
measuring the maximum diameter (A) and the minimum diameter
(B) of tumor mass with a caliper at day 0, day 6, day 12, day 18,
day 24 and day 30, respectively. The mean tumor volumes were
calculated according to the formula V=A6B2/2. At the end of
the study, mice were sacrificed by cervical dislocation and tumor
masses were removed and weighed.
Immunohistochemistry
Clinical samples were fixed for 24 h at 4uC in 4% formalde-
hyde, dehydrated and embedded in paraffin, sectioned (thickness,
5 mm) for immunohistochemical analysis of heparanase. Briefly,
after deparaffinization and rehydratation, slides were washed and
incubated with 2.5% H2O2 for 30 min to quench endogenous
peroxide activities and then were blocked with 1% bovine serum
albumin in PBS for 1 h at room temperature. A monoclonal
antibody against heparanase (1:500; Santa Cruz Biotechnologies,
Santa Cruz, CA) was used as the primary antibody for detecting
protein expression. Immunodetection was performed by incuba-
tion with a specific biotinylated secondary antibody followed by
use of the Vectastain ABC kit (Vector Laboratories, Burlingame,
CA). 3,39-Diaminobenzidine (Vector Laboratories, Burlingame,
CA) was used as the developing reagent followed by a hematoxylin
counterstain. Slides were examined under a light microscope
(Olympus, Tokyo, Japan) with a6200 magnification.
Data analysis
The chi-square test was used to analyze differences in the rate of
each variable. A two-tailed Student t-test and an analysis of
variance (ANOVA) were used to detect differences in the mean
values of the variables. A value of p less than 0.05 is considered
statistically significant. All statistical analyses were performed using
SPSS 15.0 software package (Chicago, IL, USA).
Results
Methylation status of heparanase promoter and the
effect of 5-aza-dC treatment in breast cancer cell lines
We first detected CpG methylation status of heparanase
promoter in two breast cell lines with and without 5-aza-dC
treatment using MSP and pyrosequencing, respectively. The
schematic of CpG island in heparanase promoter and regions
analyzed by MSP and pyrosequencing were illustrated in
Figure 1A and Figure 1B, respectively. In MSP, two pairs of
PCR primers were designed to span 11 CpG sites within the
heparanase promoter region. Without 5-aza-dC treatment, the
MSP detection showed that methylated CpG sites in heparanase
promoter were higher in MCF-7 cells than those in MDA-MB-435
cells. After treated with gradient concentrations of 5-aza-dC, the
intensity of bands amplified by methylated primers (MSP-M) was
significantly decreased in a dose-dependent manner, especially in
MCF-7 (Fig. 2A). Subsequently, a 58-bp region located from
2281 to 2338 in heparanase promoter containing 7 CpG sites
was analyzed by pyrosequencing. In groups of MCF-7 cells
without and with 5-aza-dC treatment, the sequencing results
showed that CpGs methylation percentage were 74.6%, 64.9%,
52.5% and 19.0%, respectively (Fig. 2B). For MDA-MB-435 cells,
the rates were 27.6%, 23.1%, 15.8% and 10.0%, respectively
(Fig. 2C). These results indicated that 5-aza-dC treatment can
inhibit DNA methylation obviously, especially in MCF-7 cells.
5-aza-dC treatment exhibit variant effect on the
expression of heparanase in MCF-7 and MDA-MB-435
cells
To further determine whether DNA methylation/demethyla-
tion played a role in heparanase expression, we tested the effect of
5-aza-dC treatment on the expression of heparanase in MCF-7
and MDA-MB-435 cells. Both conventional and Real-time PCR
demonstrated that the expression level of heparanase mRNA was
elevated paralleling with the alteration in methylation of hepar-
anase before and after 5-aza-dC treatment in MCF-7, which have
relatively low levels of heparanase mRNA before drug treatment
(Fig. 2D). For MDA-MB-435 cells, however, only a slight increase
was observed in response to 5-aza-dC treatment (Fig. 2D).
Similarly, increased expression of heparanase protein was also
only in MCF-7 cells (Fig. 2E).
5-aza-dC treatment inhibit cell proliferation of breast
cancer cells
To investigate whether methylation inhibitors were relevant to
regulating cell proliferation, flow cytometry analysis was per-
formed to detect the changes of cell cycle distribution after 5-aza-
dC treatment. Our results demonstrated that the percentage of
detected cells in S phage decreased significantly in 5-aza-dC-
treated groups compared to those in control (p,0.05; Fig. 3A).
Incubation of these cells with OGT2115, an inhibitor of
heparanase, can increase the inhibitory effect of 5-aza-dC on cell
proliferation (p,0.01; Fig. 3A). This observation indicated that, at
least in part, heparanase is involved in the changes of proliferation
in tumor cell treatment with 5-aza-dC. In addition, the
antiproliferative effect of drugs seems to be more significant in
MCF-7 than that in MDA-MB-435 cells. This observation
suggested that the antineoplastic role of 5-aza-dC is relevant to
regulating cell cycle, most likely due to an inhibition of S phase.
Demethylating agent increase the invasive capacity of
MCF-7 cells
We next carried out Matrigel invasion assay to examine the
effect of heparanase expression changes resulting from methylation
alteration on the invasive capacity of these cells. In control groups
that no drugs were applied, MDA-MB-435 cells expressing high
levels of heparanase are able to invade through the Matrigel,
whereas only few MCF-7 cells are able to penetrate the
polycarbonate membrane. In contrast, following 5-aza-dC treat-
ment, the low-invasive nature of MCF-7 cells was reversed based
on the observation that a significantly increased number of tumor
cells invaded through the Matrigel (Fig. 3B, upper panel). For
MDA-MB-435 cells, the increase of invasion potential is not
significant after drug application (Fig. 3B, lower panel). To further
confirm that heparanase plays key role in enhancing cell invasion,
OGT2115 was applied to inhibit heparanase activity. Significant
decrease of invasive capacity was observed after incubation of cells
with OGT2115, implying that the increase in tumor cell invasion
after treatment with 5-aza-dC is due to the induction of
heparanase expression (Fig. 3B).
Inhibition of DNA methylation of heparanase in MCF-7
facilitate its tumorigenesis in vivo
Regarding that the effect of drug treatment on heparanase
expression of MDA-MB-435 cells is not significantly in vitro both at
mRNA and protein level, only MCF-7 cells were selected for the
tumor formation assay in vivo. Fig. 4A showed the tumors collected
from animals at the end of experiments. The average volume of
tumor mass in the control group was significantly smaller than
HPA Methylation and Expression in Breast Cancer
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those in the treatment groups (4726133 mm3 vs 8596121 mm3,
9646193 mm3 and 12156165 mm3, respectively, Fig. 4B). Sim-
ilar results of tumor growth in vivo were observed at day 6, 12, 18
and 24, respectively. The tumor mass weights at day 30 among
groups were shown in Fig. 4C. In the control and treated (0.5 mM,
5 mM and 10 mM) groups, tumors weight were 5186172 mg,
7886190 mg, 9866387 mg and 14026331 mg, respectively
(Fig. 4C). The results indicated that demethylating agents
treatment of MCF-7 facilitate its tumorigenicity in a dose-
dependent manner.
Methylation profile of the heparanase gene in clinical
samples
To determine the DNA methylation status of heparanase in
three different groups of breast samples, methylation patterns were
examined by MSP and pyrosequencing, respectively. Among three
groups, the differences of mean age were not significant (p=0.470)
(Table 2). By MSP detection, the methylation of heparanase was
identified in 41.3% of late breast cancers (Stage IV), 80.8% of
early breast cancers (Stage I) and 90.0% of control samples
(Table 2). Representative results of MSP were shown in Fig. 5A,
indicating a decrease of DNA methylation during cancer
progression. For pyrosequencing, the plotting diagram demon-
strated that methylation of detected CpG sites fluctuated
significantly (Fig. 5B). Overall, methylation level of heparanase
promoter is lower in stages IV tumors than those of stages I tumors
and normal tissues (32.5%612.9%, 50.9%618.2% and
56.6%625.9%, respectively, Fig. 5B and Table 2). These results
implied that DNA methylation of heparanase gene can alter
dynamically during breast cancer progression.
Evaluation of heparanase expression in tissues by RT-PCR
and immunohistochemical staining
Despite that heparanase mRNA can be detected by semi-
quantitative RT-PCR in nearly all samples, the intensity of
products were elevated in tumors (Stage IV) with low-methylated
gene (Fig. 5C, left panel). These observations were further
confirmed by Real-time RT-PCR (Fig. 5C, right panel). The
results indicated that heparanase mRNA levels are inversely
correlated with the methylation status of its promoter. Represen-
tative results of RT-PCR among groups were shown in Fig. 5C.
Immunohistochemistry analyses provided similar results in protein
level (Fig. 5D).
Correlations between DNA methylation of heparanase
and clinicopathological features in breast cancer
In breast cancer samples, the correlations between DNA
methylation of heparanase and several clinicopathological param-
eters were further investigated (Table 3). Methylation status of
heparanase was classified into two groups according to the results
of MSP. The evaluated clinicopathological parameters included
tumor size, status of node metastasis, clinical stage, estrogen and
progesterone receptors (ER and PgR), and human epidermal
growth factor receptor 2 (HER2). A correlation between
heparanase methylation and clinical stage was observed
(p=0.012). In contrast, the methylation of heparanase had no
apparent associations with the following prognostic factors: tumor
size (p=0.078), node metastasis (p=0.133), ER positivity
(p=0.101), PgR positivity (p=0.528), and HER2 expression
(p=0.196).
Discussion
It is well established that breast cancer is the most common
cancer and the leading cancer-related cause of death among
women worldwide. New and better combinations of treatments
such as chemotherapy, hormonal therapy, and radiotherapy as
well as earlier detection through mammography screening
programs have contributed to the improved prognosis. The role
of heparanase in sustaining the pathology of malignant tumors was
confirmed by a variety of reports [19–21]. Both over-expression
and silencing of the heparanase gene clearly indicated the
involvement of heparanase in tumor invasion, metastasis and
Figure 1. CpG analysis and amplification regions of human heparanase gene. (A) Modified output of MethPrimer program (Li and Dahiya,
2002). Coordinates are given in relation to the transcription start site (TSS); A 355 bp CpG island (255–2411, grey region) is evident in the upstream
of the gene. Vertical lines indicate relative positions of CpG dinucleotides. (B) Schematic representation of amplification regions for Methylation-
specific PCR (MSP) and pyrosequencing. Black box indicated amplicon for MSP located at 2194–2388 relative to TSS. Region from 2281–2338
including 7 CpG dinucleotides (vertical lines in the grey box) was performed pyrosequencing reaction. Primer sequences and expected PCR product
sizes are shown in Table 1.
doi:10.1371/journal.pone.0092190.g001
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angiogenesis [22]. The preferential overexpression of heparanase
has also been demonstrated in breast cancer [23]. These studies
suggest that heparanase may be served as a molecular target for
cancer therapy.
Meanwhile, studies about heparanase regulation showed that its
expression is involved in multifaceted mechanisms [24]. In breast
malignancies, a causal role for demethylation in cancer metastasis
is supported by the fact that treatment of non-metastatic breast
cancer cells with demethylation agents increases their invasiveness,
and that treatment of invasive breast cancer with agents that
reverse demethylation results in inhibition of invasion and
metastasis [25–26]. The association between DNA hypomethyla-
tion and tumor size and histological grade for tumors further
Figure 2. Effects of 5-aza-dC on the DNA methylation and expression of heparanase in MCF-7 and MDA-MB-435 cells. (A) MSP
analyses showed that all the three different concentrations of 5-aza-dC (0.5 mM, 5 mM and 10 mM) can attenuate the DNA methylation of heparanase
in a dose-dependent manner, especially in MCF-7. The untreated cells served as a control. (B and C) Pyrosequencing results of DNA methylation
changes in MCF-7 and MDA-MB-435 cells with 5-aza-dC treatment. Quantitative analysis showed that DNA methylation of heparanase decreased
significantly in a dose-dependent manner, especially in MCF-7. (D) Analyses of mRNA abundances in MCF-7 and MDA-MB-435 cells treated with
different concentrations of 5-aza-dC (0.5 mM, 5 mM and 10 mM) by semi-quantitative RT-PCR (left panel) and Real-time RT-PCR (right panel). (E)
Western blot detections of of heparanase expression in MCF-7 and MDA-MB-435 cells treated with different concentrations of 5-aza-dC (0.5 mM, 5 mM
and 10 mM). (*p,0.05, **p,0.01 compared with the control.). Abbreviations: MSP: methylation-specific PCR; MSP-U: amplicons for unmethylated
MSP; MSP-M: amplicons for methylated MSP.
doi:10.1371/journal.pone.0092190.g002
Figure 3. Assay of cell cycle and invasion potential for MCF-7 and MDA-MB-435 cells after 5-aza-dC treatment. (A) Cell cycle
distributions of MCF-7 and MDA-MB-435 cells treated with different concentrations of 5-aza-dC (0.5 mM, 5 mM and 10 mM). The effect of heparanase
on the distribution of cell cycle was further investigated by the exposure of the cells to OGT2115 (1 mM). The percentage of S-phage cells among
groups was given in each peak plot of flow cytometry detection. (B) Matrigel assay for MCF-7 and MDA-MB-435 cells after 5-aza-dC treatment.
Specificity of heparanase in changing the cell invasive capacity was further confirmed by co-incubation of 5-aza-dC-treated cells with OGT2115
(1 mM). Cells that penetrated the polycarbonate membrane were stained with 0.1% crystal violet and examined by light microscopy (6200). The mean
number of cells per field on the lower surface of the filter was determined from ten random microscopic fields per filter and from three filters per cell
type. The untreated cells served as a control. (*p,0.05, #p,0.01 compared with the control.). Scale bar = 100 mm.
doi:10.1371/journal.pone.0092190.g003
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provides evidence for its importance in the prognosis of patients
[27].
However, mechanisms responsible for heparanase induction are
incompletely understood. In the present study, we tested whether
DNA methylation is involved in the differential regulation of
heparanase during breast cancer progression. We first detected the
expression level and methylation of CpG sites within the
heparanase promoter in MCF-7 and MDA-MB-435 cells, which
represents early stage human breast cancer with low invasive
capacity and late stage breast cancer with high metastatic capacity,
respectively. Elevated heparanase levels have been observed in
MDA-MB-435 cells in our study. Meanwhile, methylation of
promoter in heparanase is much higher in MCF-7 than that in
MDA-MB-435 cells, indicating that there is an inverse correlation
between heparanase abundance and its promoter methylation.
The result is quite consistent with previous studies regarding the
regulation of heparanase by promoter methylation in prostate and
bladder cancers [28–29].
The treatment of DNA methyltransferase inhibitors, such as 5-
aza-dC, to evaluate the DNA methylation on selected genes has
been widely accepted, and it can induce the re-expression of tumor
suppressor genes by demethylating promoter CpG sites [30–31].
In this study, after treatment with 59-azaC for 7 days, an induction
of heparanase mRNA expression and protein abundance in MCF-
7 cells resulted in an increase in invasive capacity of these cells. For
MDA-MB-435 cells, however, the reactivation of heparanase
genes by DNA demethylation is not as significant as in MCF-7
cells. These observations are plausible taking into account that
untreated MDA-MB-435 cells possess relatively low level of DNA
methylation compared with MCF-7 cells. Based on this consid-
eration, we suppose this different result may cause by cell line-
specific and dose-depend performance of 5-aza-dC. These results
are reasonable regarding the different status of DNA methylation
in both cell lines and clearly demonstrate the tight association
between the drugs induced hypomethylation and restoration of
heparanase activity at cellular levels.
As it is reported that heparanase expression is correlated with
tumor size and clinical progression stage [12], it is interesting to
speculate that heparanase may be participating in tumor growth in
vivo. Here, using breast cancer cell xenograft model, we observed
Figure 4. Role of 5-aza-dC in the tumorigenicity of MCF-7 cells in vivo. Hypodermic injection of drug-treated MCF-7 cells in nude mice
established subcutaneous xenograft tumors. On day 30 of the experiment, mice (n = 3) from each group were sacrificed and their tumors were
dissected and weighed. (A) Gross appearance of tumors on day 30. (B) Time-course measurements of tumor volume in different groups. (C) Analysis
of tumor weights in different groups on day 30. Tumor weights in drug-treated groups were significantly larger than those in control groups.
(*p,0.05 compared with the control.).
doi:10.1371/journal.pone.0092190.g004
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Figure 5. DNA methylation status and expression of heparanase in breast cancer tissues. (A) Representative results of MSP in breast
cancer tissues. (B) Pyrosequencing results of DNA methylation changes in breast cancer tissues. Quantitative analyses of DNA methylation in
heparanase among different groups were showed in the histogram. (C) Analyses of mRNA expression in breast tissues by semi-quantitative RT-PCR
(left panel) and Real-time RT-PCR (right panel). (D) Representative immune-staining of heparanase in normal control and cancer tissues (6200).
Staining of heparanase in control tissue is very weak. In contrast, the strongest expression of heparanase was observed in cancer tissues at stage IV.
Scale bar = 100 mm (*p,0.05, **p,0.01 compared with the normal control.). Abbreviations: MSP-U: amplicons for unmethylated MSP; MSP-M:
amplicons for methylated MSP; N: normal tissue; I: cancer tissue (Stage I); IV: cancer tissue (Stage IV).
doi:10.1371/journal.pone.0092190.g005
Table 2. The methylation patterns of the heparanase gene in control and breast cancer with different stage.
Control (n =10) Stage I (n=26) Stage IV (n=18) p-value
Age (years) 42.3611.6 45.4610.2 47.8612.7 0.470a
heparanase methylation cases (%) 9(90.0) 21(80.8) 7(41.3) 0.004b
Mean methylation rates (%)c 56.6625.9 50.9618.2 32.5612.9 0.001a
aANOVA.
bChi-square test.
cThe average methylation rate in a given sample was calculated from 7 CpG sites detected by pyrosequencing.
doi:10.1371/journal.pone.0092190.t002
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that BALB/c nude mice subcutaneously injected with MCF-7 cells
treated with 5-aza-dC resulted in larger tumor volume and
presented greater in tumor mass weight than those in the
untreated control group. While consistent with several previous
studies [28,32], the observations in the present study are opposite
to the findings obtained by Ateeq et al. [5]. With the fact in mind
that sequential changes of gene expression during treatment of
demethylation agents, the discrepancy may partly result from the
time of drug treatment [33–34]. Besides, the different sites of
inoculation may influence the tumor growth in vivo, because a
series of publications indicated that the behavior of cancer cells in
animal models was altered in response to the varying microenvi-
ronment resulting from incubation sites [35–36]. Further investi-
gations should be warranted to elucidate potential mechanisms
using tumors from xerografts.
It should been noted that, in many instances, changes of DNA
methylation in cultured cells in vitro are different from clinical
tissues. Therefore, it is worthy of performing further investigations
at clinical level using samples from patients. Generally consistent
with available investigations, in normal tissues, only little mRNA
and very limited protein of heparanase were detected accom-
plished by significant CpG methylation [37]. In contrast, the
expression of heparanase is predominant in cancer samples with
higher grades, whereas cytosines of CpG in these tumor tissues
were almost low-methylated. Therefore, the data show that there
is a negative correlation between methylation and protein level of
heparanase which is in line with previous reports [38–39]. When
we use TFSEARCH database (http://www.cbrc.jb/research/db/
TFSEARCH) to analyze these biased methylated CpG sites for
consensus binding sites of the known transcription factors with the
threshold score above 90.0, many transcription binding factors
including GATA-1, c-Ets and USF were predicted (data not
shown). These transcription binding factors are proved previously
that can couple with heparanase promoter and play an important
role in tumor invasion and metastasis by modulating the
remodeling of ECM [40–41]. Thus, it is reasonable to imply that
the methylation regulation mechanism of heparanase may
interfere with the binding of these transcription factors, leading
to the heparanase expression in different carcinoma stages.
Further study using proper methods, such as chromatin immuno-
precipitation assay (CHIP), to confirm these potential transcription
factors specific binding to heparanase promoter in breast
carcinoma is worth to be warranted.
In this study, we also revealed heparanase was more frequently
methylated in breast cancer samples at early stage than in those at
late stage. In contrast, no correlation was found between
heparanase methylation and prognostic factors, such as tumor
size, node metastasis, ER/PgR positivity and HER2. However, it
should be mentioned that the correlation between heparanase
expression and its status of DNA methylation is still inconclusive
for clinical samples. Several possible explanations may be
contributed to this situation. First, DNA methylation outside the
detected region of heparanase promoter might be involved, and
our MSP and pyrosequencing study only spans very limited region
in promoter [42–43]. As global epigenetic alterations in cancer, it
can be expected that the contribution of DNA methylation
alternations in single gene is limited. DNA methylation detections
in more candidate genes and more CpG sites will make the
correlations more accurate and convincing [44]. Secondly, the
limited population examined and therefore the high heterogeneity
among breast cancer patients in current study might lead to
unexpected bias. Thirdly, the regulation of heparanase is involved
many factors in addition to cytosine methylation, including
transcriptional and post-transcriptional regulation or other epige-
netic mechanisms (e.g. histone modification, small non-coding
RNA, environmental exposure induced methylation et al) [45–47].
Another important issue should be noted is the true origin of the
human MDA-MB-435 cell line. Because some melanocyte-related
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genes can be expressed in MDA-MB-435 cells, this lead to the
speculation that MDA-MB-435 cells might be melanoma rather
than breast in origin, implying that its use as a model of human
breast cancer is unsuitable [48–49]. However, recent findings
about transdifferentiation or lineage infidelity in cancers may
provide new insights into this issue. It has been demonstrated that
aberrant co-expression of multi-lineage markers via transdiffer-
entiation or lineage infidelity can occur frequently in breast
cancer, not only in cell lines but also in freshly resected specimens
[50–53]. Therefore, it may not be exclusively reliable to determine
the tissue origin of a cancer cell line based on molecular signatures
derived from gene expression profiling [54].
In summary, this study points to epigenetic control of
heparanase expression and cancer phenotype in cell lines, animal
models and clinical samples of human via site-specific DNA
methylation. Our results provide convincing evidence for cytosine
methylation as a molecular mechanism involved in transcriptional
regulation of heparanase gene expression and demonstrate that
DNA methylation of heparanase do undergo distinct changes
during breast tumor progression.
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